

PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR

FACULTAD DE CIENCIAS EXACTAS Y NATURALES

CARRERA DE MICROBIOLOGÍA

**Detección de arbovirus en mosquitos *Aedes aegypti* en dos comunidades
de Manabí, Ecuador**

Disertación previa a la obtención del título de Microbiólogo

ALVARO STEEVEN WILCA CEPEDA

Quito, 2024

CERTIFICACIÓN

Yo Anita Gabriela Villacís Salazar PhD, certifico que la disertación de Microbiología del estudiante Alvaro Steeven Wilca Cepeda ha sido concluida de conformidad con las normas establecidas; por lo tanto, puede ser presentada para la calificación.

A handwritten signature in blue ink that reads "Anita G. Villacís". The signature is fluid and cursive, with a long horizontal stroke at the bottom.

Anita G. Villacís

DIRECTORA DE LA DISERTACIÓN

Quito, 27 de febrero de 2024

DEDICATORIA

Esta investigación se la dedico a mi familia, pero principalmente a mi hermano que es y siempre será la persona más importante en mi vida. El apoyo que siempre me faltó lo pude compensar gracias a ti y sé que siempre voy a tener ese apoyo incondicional, y de igual manera lo tendrás de mi parte porque no solo eres mi hermano, si no mi amigo y mi mayor figura a seguir.

AGRADECIMIENTOS

Mis más sinceros agradecimientos van dirigidos hacia:

Mis padres Edgar Wilca y Rosa Cepeda por su apoyo durante toda mi formación académica.

Mis hermanos Edgar, Verónica y María Belén, por la espera y el apoyo en los momentos que más lo necesitaba.

A mi cuñada Johanna Gallardo y a mi cuñado Xavier Rueda, que desde el primer día que estuvimos en contacto siempre pusieron fe en mí.

A mis sobrinas Rommina Rueda, Juliana Rueda y Ana Paula Wilca, por sus ánimos y por creer en mí a pesar de todo pronóstico.

A mi novia Ambar Herrera y su familia, por su apoyo, contribución en todo el tiempo empeñado para esta investigación y por brindarme fuerzas cuando más me faltaban.

Al Centro de Investigación para la Salud en América Latina (CISeAL) - PUCE, por su acogida al momento de elaborar este estudio.

Anita Villacis, por confiar en mí y nunca decaer, pero lo más importante es agradecerle inmensamente por hacer que me apasione por la investigación. Es una de las razones principales por las que se realizó este estudio.

A Luis Solórzano, Daniel De La Cadena, Matías Cadena, mis amigos de toda la carrera, ya que siempre estuvieron cuando más los necesité.

A mis profesores de la Facultad de Ciencias Exactas y Naturales, por el crecimiento académico y personal.

Andrea López, por su acompañamiento y aporte en esta investigación.

Santiago Cadena, por el apoyo en el área de trabajo y más que todo por su amistad y comprensión.

TABLA DE CONTENIDOS

Abstract	13
Introduction	14
Material and Methods	17
Study area	17
Mosquito collection.....	17
RNA extraction in pool.....	18
cDNA Synthesis	19
End-Point PCR.....	20
Real Time PCR and Sanger Sequencing.....	20
Bioinformatic analysis.....	21
Results	21
Discussion	22
Acknowledgments	24
References	25

LISTA DE TABLAS

Tabla 1. Primers used in the three methods to detect different arboviruses.	30
Tabla 2. Results of the different arboviruses found with the three applied techniques..	31

LISTA DE FIGURAS

Figure 1. Map of Manabí, Ecuador. A. Caja Fuego, rural community. B. Andrés Vera, San Gregorio - marginal urban, both in Portoviejo County..... 32

MANUSCRITO PARA LA PUBLICACIÓN

Revista

Journal of Medical Entomology

Título

Arbovirus detection in *Aedes aegypti* mosquitoes within two communities in Manabí, Ecuador employing three molecular techniques.

Autores

Alvaro Wilca¹,

Andrea Lopez-Rosero¹,

Cesar A. Yumiseva¹,

Mario J. Grijalva^{1,2},

Anita G. Villacís^{1,2*}

Correo Electrónico

AWILCA078@puce.edu.ec

aclopezrosero@gmail.com

CAYUMISEVA@puce.edu.ec

grijalva@ohio.edu

agvillacis@puce.edu.ec

Dirección

Centro de Investigación para la Salud de América Latina (CISeAL) Pontificia
Universidad Católica del Ecuador.

Este trabajo de investigación se presenta a partir de la siguiente página en el formato de la revista científica *Journal Medical Entomology*

Wilca et al.: **Arbovirus detection in *Aedes aegypti***

Journal of Medical Entomology

Anita G. Villacís

Centro de Investigación para la Salud en América Latina (CISeAL), Pontificia Universidad Católica del Ecuador, Quito, Ecuador.

Calle Pambacienda y San Pedro del Valle, campus Nayón Phone: (593) 22991735

Fax: (593) 22991689

0 **Arbovirus detection in *Aedes aegypti* mosquitoes within two communities in**

1 **Manabí, Ecuador employing three molecular techniques.**

2

3 Alvaro Wilca-Cepeda¹, Andrea Lopez-Rosero¹, Cesar A. Yumiseva¹, Mario J.

4 Grijalva^{1,2}, Anita G. Villacís^{1*}

5

6 **Footnote**

7 ¹Centro de Investigación para la Salud en América Latina, Facultad de Ciencias Exactas
8 y Naturales, Pontificia Universidad Católica del Ecuador, Quito, Ecuador.

9 ²Infectious and Tropical Disease Institute, Department of Biomedical Sciences, Heritage
10 College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA

11

12 **Contributing authors:**

13

14 **Alvaro Wilca**

15 Address: Calle Pambacienda s/n y San Pedro del Valle, Campus Nayón, Centro de
16 Investigación para la Salud en América Latina, Pontificia Universidad Católica del
17 Ecuador, Quito, Ecuador

18 E-mail: AWILCA078@puce.edu.ec

19

20 **Andrea López- Rosero**

21 Address: Calle Pambacienda s/n y San Pedro del Valle, Campus Nayón, Centro de
22 Investigación para la Salud en América Latina, Pontificia Universidad Católica del
23 Ecuador, Quito, Ecuador

24 E-mail: aclopezrosero@gmail.com

25

26 **Cesar A. Yumiseva**

27 Address: Calle Pambacienda s/n y San Pedro del Valle, Campus Nayón, Centro de
28 Investigación para la Salud en América Latina (CISeAL), Pontificia Universidad
29 Católica del Ecuador, Quito, Ecuador

30 Telephone: +593 (2) 2991408; Fax: +593 (2) 2991689; E-mail:

31 CAYUMISEVA@puce.edu.ec

32

33 **Mario J. Grijalva.**

34 Address: 333 Irvine Hall, Ohio University, Athens, OH 45701.

35 Telephone: +1 (740) 593-2192; Fax: +1 (740) 597-2778; E-mail: grijalva@ohio.edu

36 **Anita G. Villacís**

37 Address: Calle Pambacienda s/n y San Pedro del Valle, Campus Nayón, Centro de

38 Investigación para la Salud en América Latina (CISeAL), Pontificia Universidad

39 Católica del Ecuador, Quito, Ecuador

40 Telephone: +593 (2) 2991735; Fax: +593 (2) 2991689;

41 E-mail: agvillacis@puce.edu.ec

42

43 * **Corresponding Author:** Anita G. Villacís; agvillacis@puce.edu.ec

44

45 **Abstract**

46 The arboviruses transmitted by *Aedes aegypti* cause a substantial problem in Ecuador,
47 since they can be persistent, emerging, and re-emerging. During the SARS COV-19
48 pandemic, these diseases took a backseat. As the arboviruses are transmitted by *Aedes*
49 *argypti*, the present study sought the molecular characterization of the different species
50 of arboviruses within this species of mosquito collected in two communities, Caja
51 Fuego and San Gregorio, in the province of Manabí. For this, i) a total of 468
52 mosquitoes were collected, 385 mosquitoes in the rural community of Caja Fuego and
53 83 in the marginal urban area of San Gregorio. ii) The samples were transported with all
54 permits and biosafety regulations to CISEAL. iii) The samples were homogenized
55 following the TRI Reagent® protocol. iv) Three methodologies were applied (end-
56 point PCR, RT-PCR and Sanger sequencing), and vi) different arboviruses were
57 identified. Regarding the results, flavivirus and alphavirus were identified. For
58 flavivirus, of a total of 22 samples, 18 were positive, and of these, the final point PCR
59 analysis was performed for Dengue and Zika. Nevertheless, no identification of
60 arbovirus was obtained with RT-PCR, but 2 Zika positives were detected with Sanger
61 sequencing. In contrast, there were no officially reported cases of Zika in 2023. This
62 demonstrates a possible risk of infection in the human populations who live in the Caja
63 Fuego and San Gregorio communities. It is recommended that a vigilance campaign be
64 implemented in this zone, in collaboration with the Ecuadorian Ministry of Public
65 Health.

66

67 **Keywords:** *Aedes aegypti*, Dengue, Zika, communities, Manabí, Ecuador.

68

69 **Introduction**

70 Arboviruses are a virus group belonging to the *Togaviridae* family, which are
71 characterized by their spherical form and genomic RNA. They have the capacity to be
72 transmitted by vectors such as arthropods, mainly by the genus *Aedes* mosquitoes.
73 Viruses such as Zika (ZIKV), Dengue (DENV) and Chikungunya (CHIKV), cause high
74 rates of morbidity and mortality worldwide. *Aedes aegypti*'s life cycle is developed in
75 four phases: egg, larvae, pupa, and adult, which is why it is considered a
76 holometabolous species. However, the epidemiology of the arboviruses is complex due
77 to diverse factors such as: i) adult *A. aegypti* females being exclusively responsible for
78 the transmission of the arboviruses through human blood consumption (Velandia-
79 Romero et al., 2017), ii) socioeconomic circumstances (Alvarado-Prado & Nieto, 2019),
80 iii) climate change (Alvarado-Prado & Nieto, 2019), iv) natural disasters (Alvarado-
81 Prado & Nieto, 2019) and v) human mobilizations, as these lead to an increase in the
82 mosquito population (Alvarado-Prado & Nieto, 2019). For this reason, *A. aegypti* has
83 been able to expand to new geographical locations. These variations have resulted in the
84 ability of this vector to colonize new habitats in which it had not been previously
85 present (Alvarado-Prado & Nieto, 2019).

86 The epidemiological importance of *A. aegypti* resides not only in its capacity to host
87 the different types of Dengue, Zika and Chikungunya viruses, but in the fact that they
88 are most common in tropical and subtropical zones within America, Africa, Asia, and
89 Oceania. Transmission is also significant in areas where these mosquitoes are not
90 commonly found, but still inhabit (Betancourt-Cravioto & Falcón-Lezama, 2020).

91 This may pose a challenge for the healthcare systems and could require control
92 measures and effective preventative strategies. It is also necessary to consider that an
93 epidemic may have a high impact in a country's economy, decreasing its labor

94 productivity, tourism, and commerce in rural and urban areas, while increasing medical
95 care costs (Castañeda- Porras & Zuleta-Dueñas, 2017).

96 According to Pan American Health Organization (PAHO), the transmission of
97 diseases generated by Dengue, Zika and Chikungunya has increased in the Americas
98 between 2013 and 2017. Additionally, there has been no significant control strategy
99 implemented for the reduction of diseases such as hemorrhagic fever, dengue fevers,
100 among others (WHO, 2023). Globally, the reported development of diseases linked to
101 these arboviruses is 17% when compared to other diseases, and left untreated, represent
102 1 million deaths per year (Uribe-Álvarez & Félix, 2017).

103 Dengue is the arbovirus within Vector-Borne Diseases (VBD) that causes the
104 majority of deaths in the Americas, with an outbreak frequency of 3 to 5 years (MSP,
105 2020b). There was an increase in the recorded cases of Dengue virus in the Americas in
106 2018. In 2019, Ecuador reported 8,419 cases of Dengue, of which 1,718 cases (20.47%)
107 had warning signs. The lethality rate was 0.044% (MSP, 2015). In 2022, there were
108 16,017 notified, confirmed cases of Dengue. Of these, 14,133 (88.23%) were Dengue
109 with no warning signs, 1,775 cases (11.08%) were Dengue with warning signs and 109
110 cases (0.68%) were severe Dengue, with circulating serotypes DENV-1 and DENV-2
111 (MSP, 2023b). Additionally, during 2014-2020 in Manabí, the rate of Dengue per
112 100,000 inhabitants was 84.61% (MSP, 2020a).

113 Similarly, since Zika's arrival to America in 2014, there has been an unusual increase
114 in microcephaly. By 2016, there were 4,180 cases reported in Ecuador due to Zika-
115 associated infections. The presence of Zika increased exponentially by 85% after the
116 2016 earthquake (Valero-Cedeño et al., 2020).

117 Finally, Chikungunya cases have been registered since 2013, giving origin to over
118 1.3 million infections in 43 countries within the American continent. In May 2015, in

119 Ecuador, Chikungunya registered a 25% increase of infections. There were 33,619
120 recorded cases in 2015; 1,860 cases in 2016; 196 in 2017; 8 in 2018; 2 in 2019 and 1 in
121 2020 (Valero-Cedeño et al., 2020). However, in 2022 viruses such as Chikungunya and
122 Zika, which are transmitted by the same vector (*Aedes aegypti*), have not been notified
123 (MSP, 2023b).

124 Currently, diverse endemic diseases have been left aside due to the pandemic
125 generated by SARS COV-19. This has resulted in a lack of control and follow-up in
126 other diseases, with the consequence of an increase in Dengue, Zika and Chikungunya
127 cases. Additionally, climatic changes have favored the increase of the populations of the
128 arbovirus vector (*Aedes aegypti*), which could imply an extensive spread of these viral
129 diseases (Segarra & Rubio, 2017).

130 Previous studies based in Ecuador do not prioritize the analysis of mosquitoes in the
131 area occupied by the diseases caused by arbovirus. Instead, they are more focused on
132 the mosquitoes' geographical adaptability and their resistance to specialized chemicals
133 utilized for their control. Some of these studies are: i) Seasonal and geographic variation
134 in insecticide resistance in *Aedes aegypti* in southern Ecuador (Ryan et al., 2019) and ii)
135 Resistance status of *Aedes aegypti* to deltamethrin, malathion, and temephos in Ecuador
136 (Morales et al., n.d.).

137 Therefore, the aim of this study was the molecular characterization of the different
138 species of arboviruses in *Aedes aegypti* collected in two communities, Caja Fuego and
139 San Gregorio, in the Manabí province, using multiplex real-time RT-PCR. With these
140 results the goal is to reduce the risk of infection in the Manabí province, and we expect
141 that the gathered information raises awareness among the population of these endemic
142 areas, regardless of their social group, which is directly involved in the arboviral

143 diseases (Santiago et al., 2018). This will allow the implementation of a surveillance
144 system in the future, not just by the authorities, but also by society in general.

145

146 **Material and Methods**

147

148 **Study area**

149 The samples of this study were collected in the Manabí province, in two communities,
150 (Caja Fuego - rural community) and Andrés Vera (San Gregorio - marginal urban)
151 ranging from 65 to 400 meters above sea level (masl), located in a single county,
152 Portoviejo (Fig. 1).

153 Manabí province has a tropical and subtropical climate, this province presents six
154 vegetation zones: deciduous forest, semi-deciduous forest, low mountain green forest,
155 cloud forest, dry-montane shrub forest and tropical savannah (Grijalva et al., 2017). In
156 the rural communities, agriculture is the main economic activity with a predominance of
157 sugar cane, oranges, bananas, yucca, corn and rice. In addition, some palms such as
158 cade or tagua (*Phytelephas aequatorialis*) and coconuts are cultivated. Most of the walls
159 and floors of the houses are constructed with bamboo cane “caña guadúa” (*Guadua*
160 *angustifolia*) or wood, and the roofs are commonly made of cade palm fronds, with a
161 few made of zinc (Black et al., 2007; Villacís et al., 2017). The houses within the
162 marginal-urban communities usually have brick walls, cement floors and zinc roofs
163 (USGP et al., 2021).

164

165 **Mosquito collection**

166 The mosquito, *Aedes aegypti*, collection was in May of 2023 during the rainy season.
167 This was carried out with a collection permit (MAAE-DBI-CM-2021-0185) and
168 mobilization permit (MAAE-CMARG-2020-0178). The selected houses were

169 georeferenced using a global positioning system, (a single GPS point), thus obtaining a
170 unique identification code for each collection site. The mosquitoes were collected using
171 i) electric aspirators, Prokopack, due to its suction power, lightweight (0.5-kg) low rate
172 of power consumption (4.3 amps), and water resistance. A 4:3-inch flexible rubber
173 coupling (PlumbQuick model P1056-43, Fernco Inc., Davison, MI) (Vazquez-Prokopec
174 et al., 2009), and ii) manual aspirators through a filter-equipped mouthpiece, ensuring
175 the mosquitoes remained in good condition. In addition, at the field, aided by a
176 stereoscope, *A. aegypti* was identified, and the sex was determined. This process was
177 carried out with the personnel of the Centro de Investigación para la Salud en América
178 Latina (CISeAL) and Ecuadorian Ministry of Public Health (MSP).

179 Subsequently, the mosquitoes were grouped in sets of 10 and placed in tubes
180 containing 1000µl of TRI Reagent® solution. It is worth noting that the tubes with
181 mosquitoes were kept at optimal temperatures for further processing in the laboratories
182 of the CISeAL.

183

184 **RNA extraction in pool**

185 For the homogenization of the mosquitoes, plastic pestles were used and care was taken
186 to avoid leaving any residue or large pieces, following the recommendations of TRI
187 Reagent® to prioritize obtaining a good amount of RNA. Three washes of the RNA
188 pellets were performed. First, 200µl of chloroform (CHCL₂) was added per 1000µl of
189 Trizol, vigorously agitated, and incubated for 15 minutes at room temperature;
190 afterwards, it was centrifuged for 15 minutes at 12,000 RPM, 4°C, and the supernatant
191 was transferred to a new tube. Second, 800µl of isopropanol (C₃H₈O) was added per
192 100µl of the new supernatant, vortexed for a few minutes, and incubated for 30 minutes
193 at -80°C; then, it was centrifuged for 30 minutes at 12,000 RPM, 4°C, resulting in a new

194 pellet. Third, the pellet was washed with 1000µl of 75% molecular ethanol (EtOH),
195 passed through a vortex, and underwent a final centrifugation for 5 minutes at 7,500
196 RPM, 4°C. Finally, the pellet was re-suspended in 50µl of nuclease-free water.
197 However, two aliquots were taken from the 50µl, one of 35µl, which was stored at -
198 80°C, and another of 15µl at -20°C, for subsequent analysis (López-Rosero et al., in
199 prep).

200

201 **cDNA Synthesis**

202 The extracted RNA samples were converted to cDNA by following the Promega-
203 GoScript Reverse Transcription Kit protocol. This process was divided into two stages:
204 First, a mixture of 2 µl of nuclease-free water, 1 µl of random primers, and 2 µl of RNA
205 sample was created. This first mixture was heated for 5 mins at 70°C to linearize the
206 RNA, then it was frozen for 5 mins at 4°C, and finally, the mixture was exposed to
207 centrifugal force for 10 seconds at 7.500 RPM. Second, the retrotranscription mix was
208 prepared. 6.5 µl of nuclease-free water were mixed with 4 µl of GoScript 5X reaction
209 buffer, 2 µl of MgCl₂, mM, 1 µl of PCR nucleotide mix, 0.5 µl of RNAase, and 1 µl of
210 GoScript reverse transcriptase.

211 Once the creation of the mixture was finalized, the retrotranscription mix was
212 combined with the linearized RNA (final volume 20 µl). Afterwards, it was placed into
213 the thermo-cycler with the following settings: 25°C for 5 mins, 42°C for 1 hour, and
214 70°C for 15 mins. After the cDNA was obtained, it was stored at -80°C for the next
215 analysis (López-Rosero et al., in prep).

216 After synthesizing and preserving the cDNA at -80°C, three techniques were used for
217 the identification of arbovirus: i) End-Point PCR, ii) Real Time PCR and iii) Sanger
218 Sequencing.

219

220 **End-Point PCR.**

221 Flavivirus: A mix was prepared with 11.25 µl of nuclease-free water, 5 µl of buffer 5X
222 green, 2 µl MgCl₂ mM, 0.5 µl of nucleotide mix 10 mM, 2.5 µl of primer forward
223 (CFD2), 2.5 µl of primer reverse (MA) (Table 1), 0.25 µl GoTaq and 1 µl of sample. The
224 amplification of the samples was configured in the thermo-cycler in the following way:
225 i) 94°C for 2 mins, ii) 35 cycles of: 94°C for 45 seconds, 55°C for 1 min, and 72°C for 1
226 min, iii) 72°C for 7 mins (Kuno, 1998).

227 For Dengue, the same protocol was followed for the creation of the mixture, as well
228 as the thermo-cycler settings that were mentioned in Flavivirus. The only difference was
229 the primers. In Dengue, the primer used for forward was (D1-F), and for the reverse
230 (D2-R) (Table 1) (Lanciotti et al., 1992).

231 However, for Zika, there were only a few changes in the protocol for the creation of
232 the mixture because 8.34 µl of nuclease-free water, 3.8 µl of primer forward
233 (ZIKVENVF), and 4.11 µl of primer reverse (ZIKVENVR) (Table 1) were added.
234 Furthermore, there were changes in the thermo-cycler settings. These were: i) 95 °C for
235 2 mins, ii) 35 cycles of: 95°C for 20 seconds, 55°C for 20 seconds, 68°C for 30 seconds,
236 iii) 68°C for 7 mins (Faye et al., 2008).

237 The samples for all three cases were revealed in 1.5% agarose gels with ethidium
238 bromide as an intercalating agent.

239

240 **Real Time PCR and Sanger Sequencing**

241 For the detection of Zika, Dengue and Chikungunya multiplex, a *bioPerfectus* kit was
242 used. For this procedure, the *bioPerfectus* procedure was followed, utilizing a Bio-Rad

243 detection machine in real time, being this one of the pieces of equipment that can be
244 used for the acquired kit (bio*Perfectus* technologies, 2021).
245 Once the samples were analyzed with the RT-PCR kit, the Sanger sequencing was
246 proposed and practiced with the goal of verifying data. 4 independent reactions were
247 carried out, each one mixed with: the amplicon mixtures acquired during the End-Point
248 PCR analysis for Dengue and Zika, primers for Dengue and Zika (Table 1), 4 2'-
249 deoxynucleotides (dNTP) and 4 dideoxynucleotides (ddNTP), with one of these four in
250 a lower proportion. Once the synthesis was obtained, the fragments were identified in a
251 polyacrylamide gel (SEIMC, 2021).

252

253 **Bioinformatic analysis**

254 Once the results of the Sanger sequencing were obtained, the synthesized sequences
255 were read with the Geneious Prime software. The starting point was the general
256 assembly of Dengue and another general assembly of Zika. This allowed the distinction
257 of which samples managed to align, which led to the cleansing of the sequences.

258 Once finalized, the National Center for Biotechnology Information's (NCBI)
259 nucleotide tool BLAST was used for the identification of the assembled samples.

260

261 **Results**

262 The total amount of mosquitoes collected in the two Manabí communities was 468
263 specimens, grouped in 72 pools. Of those specimens, a total of 385 mosquitoes, 62
264 males and 323 females were collected in Caja Fuego. While 83 mosquitoes, 40 males
265 and 43 females, were found in the San Gregorio community. The mosquito recollection
266 was within the expected parameters in the rainy season.

267 In the end point PCR, 11 positive samples for Dengue and 7 for Zika were observed,
268 however, the results of the RT-PCR did not detect any arboviruses. Of the 72 initial
269 pools, only 2 Zika positive pools were obtained with Sanger sequencing (samples 21
270 and 53) (2.78%), corresponding to one within the Comunidad Caja Fuego and another
271 for San Gregorio; it must be mentioned that both pools are from female samples of *A.*
272 *aegypti*. The comparative results of the three techniques used for the identification of
273 arbovirus in *A. aegypti* are shown in the following table (Table 2).

274

275 **Discussion**

276 The information about arboviruses is very important in Ecuador, as these are the causes
277 of various high-impact pathologies within Ecuadorian society and may cause death to
278 the hosts of these viruses. Due to the increasing health burden posed by endemic
279 diseases transmitted by the Dengue, Zika, and Chikungunya viruses, it is important to
280 implement new techniques which facilitate the detection and identification of these
281 viruses; not only in humans, but simultaneously in their vectors, improving their
282 control.

283 In this study, of the three techniques used, it is speculated that most sensitive is the
284 RT-PCR multiplex (bio*Perfectus* technologies, 2021). This technique is extremely
285 important due to the benefit of higher sensitivity and the amplification of multiple
286 viruses at a time in comparison to the traditional method. However, in the case of this
287 study, the quality of the samples was very poor and a possible degradation in RNA
288 could be deduced. This could have happened due to i) the isolation with Trizol, ii)
289 transportation time, iii) long time periods in which the sample was exposed to room
290 temperatures (Hernández-Ruiz et al., 2019).

291 The kit used for RT-PCR has limitations in its use, such as: i) negative results do not
292 exclude the presence of Zika, Dengue and Chikungunya; therefore, it must not be
293 considered as the only detection parameter, ii) results depend on collection of the
294 mosquitoes, transportation, storage, and their later processing, iii) false negatives due to
295 the presence of inhibitors, iv) false negatives as demonstrated through the Sanger
296 sequencing results, and v) evolution of viruses and mutations (bio*Perfectus*
297 technologies, 2021).

298 In this study, the results obtained through Sanger sequencing (2 positive Zika
299 samples) draw attention to the MSP report in the Manabí province. In 2023, there were a
300 total of 99 Dengue cases reported within Manabí. However, there were no reported
301 cases of Zika (MSP, 2023b). The analysis has made it evident that there are
302 discrepancies when comparing the report with this study's results. This demonstrates
303 that people within the collection zones where these mosquitoes were acquired find
304 themselves at risk of infection due to the Zika virus.

305 Finally, in order to limit the degradation of RNA samples, modifying the extraction
306 protocol is recommended to reduce the exposure times of the samples when they are
307 handled (Liu & Harada, 2013).

308 To obtain more information about these arboviruses and complement the studies of
309 any of these techniques used (end point PCR, RT-PCR multiplex, and sanger
310 sequencing) the following are recommended: i) purification of the samples, ii) increase
311 in sample size, employment of CAP questionnaires, and iii) implementation of serology
312 studies. These are vital to acquire a comprehensive overview of the aforementioned
313 diseases, and all its protagonists.

314 In conclusion, it is sought to give a better concept, vision, and reduction in the time it
315 takes to identify Dengue, Zika and Chikungunya in set populations without direct

316 intervention towards the humans, additionally reducing the risk of infection, alerting the
317 communities, and implementing better vigilance campaigns in this way, together with
318 MSP.

319

320 **Acknowledgments**

321 Special thanks are extended to the inhabitants of the communities visited. Additionally,
322 we want to thank the staff of the Ecuadorian Ministry of Public Health (MSP),
323 Francisco Párraga and Freddy Véliz, for their cooperation and assistance in the field.

324 Financial support for the laboratory work was received from Pontificia Universidad
325 Católica del Ecuador (Fondo público, number QINV0340-IINV502000000). The
326 fieldwork for this project was provided by the study titled: A novel framework to
327 predict the transmission of mosquito-borne diseases under climate change
328 (QAUF0860).

329

330

331 **References**

- 332 Alvarado-Prado, R., & Nieto, E. (2019). *Factores socioeconómicos y ambientales*
333 *asociados a la incidencia de dengue: estudio ecológico en Costa Rica, 2016.*
334 <https://www.scielo.sa.cr/pdf/rcsp/v28n2/1409-1429-rcsp-28-02-227.pdf>
- 335 Betancourt-Cravioto, M., & Falcón-Lezama, J. (2020). *Arbovirus y salud pública.*
336 [https://www.revistaciencia.amc.edu.mx/images/revista/71_1/PDF/04_71_1_1202_](https://www.revistaciencia.amc.edu.mx/images/revista/71_1/PDF/04_71_1_1202_Arbovirus.pdf)
337 [Arbovirus.pdf](https://www.revistaciencia.amc.edu.mx/images/revista/71_1/PDF/04_71_1_1202_Arbovirus.pdf)
- 338 bioPerfectus technologies. (2021). *Bioperfectus Technologies Zika Virus Real Time PCR*
339 *Kit Version 1.0 Issue Zika Virus/Dengue Virus/Chikungunya Virus Real Time PCR*
340 *Kit INSTRUCTIONS FOR USE.* www.bioperfectus.com
- 341 Black, C. L., Ocaña, S., Riner, D., Costales, J. A., Lascano, M. S., Davila, S., Arcos-
342 Teran, L., Seed, J. R., & Grijalva, M. J. (2007). Household risk factors for
343 *Trypanosoma cruzi* seropositivity in two geographic regions of Ecuador. *Journal of*
344 *Parasitology*, 93(1), 12–16. <https://doi.org/10.1645/GE-899R.1>
- 345 Castañeda- Porras, O., & Zuleta-Dueñas, L. (2017). *Conocimientos, actitudes y*
346 *prácticas para el control de enfermedades transmitidas por vectores en zona rural*
347 *dispersa, San Luis de Palenque, Casanare-Colombia, 2017.*
348 <http://www.scielo.org.co/pdf/rmri/v24n2/0122-0667-rmri-24-02-108.pdf>
- 349 Faye, O., Faye, O., Dupressoir, A., Weidmann, M., Ndiaye, M., & Alpha Sall, A. (2008).
350 One-step RT-PCR for detection of Zika virus. *Journal of Clinical Virology*, 43(1),
351 96–101. <https://doi.org/10.1016/j.jcv.2008.05.005>
- 352 Grijalva, M. J., Villacís, A. G., Moncayo, A. L., Ocaña-Mayorga, S., Yumiseva, C. A., &
353 Baus, E. G. (2017). Distribution of triatomine species in domestic and peridomestic
354 environments in central coastal Ecuador. *PLoS Neglected Tropical Diseases*,
355 11(10). <https://doi.org/10.1371/journal.pntd.0005970>

356 Hernández-Ruiz, P., Aguirre-García, M. M., & Pamela Gómez-García, A. (2019).
357 *Qualitative and Quantitative Analysis of RNA extracted from Pulp Human Tissue.*
358 <https://www.researchgate.net/publication/364384909>

359 Kuno, G. (1998). Universal diagnostic RT-PCR protocol for arboviruses. *Journal of*
360 *Virological Methods*, 72, 27–41.

361 Lanciotti, R. S., Calisher, C. H., Gubler, D. J., Chang, G.-J., & Vorndamt, A. V. (1992).
362 Rapid Detection and Typing of Dengue Viruses from Clinical Samples by Using
363 Reverse Transcriptase-Polymerase Chain Reaction. *JOURNAL OF CLINICAL*
364 *MICROBIOLOGY*, 30(3), 545–551.

365 Liu, X., & Harada, S. (2013). RNA isolation from mammalian samples. *Current*
366 *Protocols in Molecular Biology*, SUPPL.103.
367 <https://doi.org/10.1002/0471142727.mb0416s103>

368 López-Rosero, A., Sippy, R., Stewart-Ibarra, A. M., Ryan, S. J., Mordecai, E., Heras, F.,
369 Beltrán, E., Costales, J. A., & Neira, M. (2018). *High prevalence of Zika virus*
370 *infection in populations of Aedes aegypti from South-Authors.*

371 Morales, D., Ponce, P., Cevallos, V., Espinosa, P., Vaca, D., & Quezada, W. (n.d.).
372 *RESISTANCE STATUS OF AEDES AEGYPTI TO DELTAMETHRIN,*
373 *MALATHION, AND TEMEPHOS IN ECUADOR.*
374 [http://meridian.allenpress.com/jamca/article-pdf/35/2/113/2867835/i8756-971x-35-](http://meridian.allenpress.com/jamca/article-pdf/35/2/113/2867835/i8756-971x-35-2-113.pdf)
375 [2-113.pdf](http://meridian.allenpress.com/jamca/article-pdf/35/2/113/2867835/i8756-971x-35-2-113.pdf)

376 MSP. (2015). *SUBSISTEMA DE VIGILANCIA SIVE-ALERTA ENFERMEDADES*
377 *TRANSMITIDAS POR VECTORES ECUADOR, SE 16-2021.*

378 MSP. (2020a). *ENFERMEDADES TRANSMITIDAS POR VECTORES DENGUE.*
379 *Ecuador, SE 01-14/ 2020.* [https://www.salud.gob.ec/wp-](https://www.salud.gob.ec/wp-content/uploads/2020/04/DENGUE-SE_14_2020_GACETA.pdf)
380 [content/uploads/2020/04/DENGUE-SE_14_2020_GACETA.pdf](https://www.salud.gob.ec/wp-content/uploads/2020/04/DENGUE-SE_14_2020_GACETA.pdf)

381 MSP. (2020b). *GACETAS VECTORIALES – Ministerio de Salud Pública*.
382 <https://www.salud.gob.ec/gacetatas-vectoriales/>

383 MSP. (2023a). *Se mantiene vigilancia epidemiológica ante casos de virus respiratorios,*
384 *dengue, chikungunya, leptospirosis y alcohol metílico.*
385 [https://www.salud.gob.ec/se-mantiene-vigilancia-epidemiologica-ante-casos-de-](https://www.salud.gob.ec/se-mantiene-vigilancia-epidemiologica-ante-casos-de-virus-respiratorios-dengue-chikungunya-leptospirosis-y-alcohol-metilico/#:~:text=El%20subsecretario%20Nacional%20de%20Vigilancia,chikungunya%2C%20leptospirosis%20y%20alcohol%20met%C3%ADlico.)
386 [virus-respiratorios-dengue-chikungunya-leptospirosis-y-alcohol-](https://www.salud.gob.ec/se-mantiene-vigilancia-epidemiologica-ante-casos-de-virus-respiratorios-dengue-chikungunya-leptospirosis-y-alcohol-metilico/#:~:text=El%20subsecretario%20Nacional%20de%20Vigilancia,chikungunya%2C%20leptospirosis%20y%20alcohol%20met%C3%ADlico.)
387 [metilico/#:~:text=El%20subsecretario%20Nacional%20de%20Vigilancia,chikungu](https://www.salud.gob.ec/se-mantiene-vigilancia-epidemiologica-ante-casos-de-virus-respiratorios-dengue-chikungunya-leptospirosis-y-alcohol-metilico/#:~:text=El%20subsecretario%20Nacional%20de%20Vigilancia,chikungunya%2C%20leptospirosis%20y%20alcohol%20met%C3%ADlico.)
388 [nya%2C%20leptospirosis%20y%20alcohol%20met%C3%ADlico.](https://www.salud.gob.ec/se-mantiene-vigilancia-epidemiologica-ante-casos-de-virus-respiratorios-dengue-chikungunya-leptospirosis-y-alcohol-metilico/#:~:text=El%20subsecretario%20Nacional%20de%20Vigilancia,chikungunya%2C%20leptospirosis%20y%20alcohol%20met%C3%ADlico.)

389 MSP. (2023b). *SUBSECRETARIA DE VIGILANCIA, PREVENCIÓN Y CONTROL DE*
390 *LA SALUD DIRECCIÓN NACIONAL DE VIGILANCIA EPIDEMIOLÓGICA*
391 *ENFERMEDADES TRANSMITIDAS POR VECTORES.*
392 https://www.salud.gob.ec/wp-content/uploads/2023/02/Gaceta-SE-3_2023.pdf

393 Ryan, S. J., Mundis, S. J., Aguirre, A., Lippi, C. A., Beltrán, E., Heras, F., Sanchez, V.,
394 Borbor-Cordova, M. J., Sippy, R., Stewart-Ibarra, A. M., & Neira, M. (2019).
395 Seasonal and geographic variation in insecticide resistance in *Aedes aegypti* in
396 southern Ecuador. *PLoS Neglected Tropical Diseases*, 13(6).
397 <https://doi.org/10.1371/journal.pntd.0007448>

398 Santiago, G. A., Vázquez, J., Courtney, S., Matías, K. Y., Andersen, L. E., Colón, C.,
399 Butler, A. E., Roulo, R., Bowzard, J., Villanueva, J. M., & Muñoz-Jordan, J. L.
400 (2018). Performance of the Trioplex real-time RT-PCR assay for detection of Zika,
401 dengue, and chikungunya viruses. *Nature Communications*, 9(1).
402 <https://doi.org/10.1038/s41467-018-03772-1>

403 Segarra, C. S., & Rubio, D. G. (2017). Contribución de Ecuador a la utilización de la
404 clasificación de dengue de la OMS 2009 Contribution of Ecuador to the use of the

405 WHO 2009 dengue classification. *Revista Cubana de Medicina Tropical*, 69(2).
406 <http://scielo.sld.cu>

407 SEIMC. (2021). *Aplicaciones de las técnicas de secuenciación masiva en la*
408 *Microbiología Clínica*.
409 [https://seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/s](https://seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimiento71.pdf)
410 [eimc-procedimiento71.pdf](https://seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimiento71.pdf)

411 Uribe-Álvarez, C., & Félix, N. C. (2017). *Las enfermedades transmitidas por vectores y*
412 *el potencial uso de Wolbachia, una bacteria endocelular obligada, para*
413 *erradicarlas* (Vol. 60). [https://www.scielo.org.mx/pdf/facmed/v60n6/2448-4865-](https://www.scielo.org.mx/pdf/facmed/v60n6/2448-4865-facmed-60-06-51.pdf)
414 [facmed-60-06-51.pdf](https://www.scielo.org.mx/pdf/facmed/v60n6/2448-4865-facmed-60-06-51.pdf)

415 USGP, APGRE, & GIZ. (2021). *Implementación colaborativa de medidas de*
416 *adaptación basadas en la naturaleza y mejoramiento del espacio público en zonas*
417 *de riesgo de deslizamiento en las colinas de Portoviejo*.
418 [https://www.bivica.org/files/5799_2021.03.11%20Dise%C3%B1o%20colaborativo](https://www.bivica.org/files/5799_2021.03.11%20Dise%C3%B1o%20colaborativo%20medidas%20adaptaci%C3%B3n%20Portoviejo.pdf)
419 [%20medidas%20adaptaci%C3%B3n%20Portoviejo.pdf](https://www.bivica.org/files/5799_2021.03.11%20Dise%C3%B1o%20colaborativo%20medidas%20adaptaci%C3%B3n%20Portoviejo.pdf)

420 Valero-Cedeño, N., Baque-Arteaga, K., Calderón-Pico, A., Caiza-Defaz, C., & Escobar-
421 Rivera, M. (2020). *Prevalencia de zika y chikungunya en los cantones de Jipijapa*
422 *y Puerto López de la Provincia de Manabí, Ecuador. 2015-2020*. 46(6), 968–981.
423 <https://doi.org/10.23857/pc.v6i2.2247>

424 Vazquez-Prokopec, G. M., Galvin, W. A., Kelly, R., & Kitron, U. (2009). A New, Cost-
425 Effective, Battery-Powered Aspirator for Adult Mosquito Collections NIH Public
426 Access. In *J Med Entomol* (Vol. 46, Issue 6). www.rule-industries.com

427 Velandia-Romero, M., Olano, V., Coronel-Ruiz, C., Cabezas, L., Calderón-Peláez, M.,
428 Castellanos, J., & Matiz, M. (2017). Detección del virus del dengue en larvas y
429 pupas de *Aedes aegypti* recolectadas en áreas rurales del municipio de Anapoima,

430 Cundinamarca, Colombia. *Biomedica*.
431 <https://revistabiomedica.org/index.php/biomedica/article/view/3584/3713>
432 Villacís, A. G., Marcet, P. L., Yumiseva, C. A., Dotson, E. M., Tibayrenc, M., Brenière,
433 S. F., & Grijalva, M. J. (2017). Pioneer study of population genetics of *Rhodnius*
434 *ecuadoriensis* (Hemiptera: Reduviidae) from the central coast and southern Andean
435 regions of Ecuador. *Infection, Genetics and Evolution*, 53, 116–127.
436 <https://doi.org/10.1016/j.meegid.2017.05.019>
437 WHO. (2023). *Expansión geográfica de los casos de dengue y chikungunya más allá de*
438 *las áreas históricas de transmisión en la Región de las Américas*.
439 <https://www.who.int/es/emergencies/disease-outbreak-news/item/2023-DON448>
440
441

442 **Tabla 1.** Primers used in the three methods to detect different arboviruses.

	Primer pair (code)	Amplicon	Source
Flavivirus	MA: 5'-CATGATGGGRAARAGRGARRAG-3'	260 pb	(Kuno, 1998)
	CFD2: 5'-GTGTCCCAGCCGGCGGTGTCATCAGC-3'		
Dengue	D1-F: 5'-TCAATATGCTGAAACGCGCGAGAAACCG-3'	511 pb	(Lanciotti et al., 1992)
	D2-R: 5'-TTGCACCAACAGTCAATGTCTTCAGGTTTC-3'		
Zika	ZIKVENVF: 5'-GCTGGDGCRGACACHGGRAC-3'	364 pb	(Faye et al., 2008)
	ZIKVENVR: 5'-RTCYACYGCCATYTGGRCTG-3'		

443

444

445

446 **Table 2.** Results of the different arboviruses found with the three applied techniques.

447


	End-Point PCR	RT-PCR kit (<i>bioPerfectus</i>)	Sanger sequencing
Flavivirus	>75%	N/A	N/A
Dengue	11	0	0
Zika	7	0	2

448

449

Figure Legends

450



451

452 **Figure 1.** Map of Manabí, Ecuador. A. Caja Fuego, rural community. B. Andrés Vera,

453 San Gregorio - marginal urban, both in Portoviejo County.

454

455
456
457

Formatting

458 For new submissions, our formatting requirements are simple—just make sure your
459 paper has the following items:

- 460 • Continuous line numbers
 - 461 • Double-spaced lines
 - 462 • A title page and abstract in the main document
 - 463 • A main document in a doc, docx, tex (converted to PDF for review) or rtf file type
 - 464 • Tables in a Word document (we cannot accept Excel files, unless they are
465 supplementary files)
 - 466 • Figure and table legends in the main document
 - 467 • All coauthors entered into the online review system (email addresses required)
- 468 Please note there are more formatting guidelines for revised versions, as those are closer
469 to being accepted (see the Revised Versions section of these author instructions).
- 470 • References listed in alphabetical order, cited by author and year in the text (not
471 numbered)
 - 472 • Figures and tables at the end of the main document after the references, or uploaded
473 as separate files. Figure legends should be included at the end of the main text after
474 the references, and table legends should be next to their corresponding tables
 - 475 • Text is single-column
- 476

477 **Author Contribution Statements**

478 The contributions of all authors must be provided during the article submission
479 process. This journal uses the [CRediT Taxonomy](#) to describe each author’s individual
480 contributions to the work, and there will be a step during submission to select all
481 relevant contributions from each author. The roles selected during submission will
482 automatically be included in an author contribution statement placed after the
483 acknowledgments in the published paper. While the submitting author is responsible for
484 selecting the contributions, all authors should have agreed to their individual
485 contributions before submission, and all contributions listed should be accurate.

486

487 The 14 contributor roles available are:

- 488 • Conceptualization – Ideas; formulation or evolution of overarching research goals
489 and aims.
- 490 • Data curation – Management activities to annotate (produce metadata), scrub data
491 and maintain research data (including software code, where it is necessary for
492 interpreting the data itself) for initial use and later re-use.
- 493 • Formal analysis – Application of statistical, mathematical, computational, or other
494 formal techniques to analyze or synthesize study data.
- 495 • Funding acquisition - Acquisition of the financial support for the project leading to
496 this publication.
- 497 • Investigation – Conducting a research and investigation process, specifically
498 performing the experiments, or data/evidence collection.
- 499 • Methodology – Development or design of methodology; creation of models.
- 500 • Project administration – Management and coordination responsibility for the research
501 activity planning and execution.
- 502 • Resources – Provision of study materials, reagents, materials, patients, laboratory
503 samples, animals, instrumentation, computing resources, or other analysis tools.

- 504 • Software – Programming, software development; designing computer programs;
- 505 implementation of the computer code and supporting algorithms; testing of existing
- 506 code components.
- 507 • Supervision – Oversight and leadership responsibility for the research activity
- 508 planning and execution, including mentorship external to the core team.
- 509 • Validation – Verification, whether as a part of the activity or separate, of the overall
- 510 replication/reproducibility of results/experiments and other research outputs.
- 511 • Visualization – Preparation, creation and/or presentation of the published work,
- 512 specifically visualization/data presentation.
- 513 • Writing – original draft – Preparation, creation and/or presentation of the published
- 514 work, specifically writing the initial draft (including substantive translation).
- 515 • Writing – review & editing – Preparation, creation and/or presentation of the
- 516 published work by those from the original research group, specifically critical
- 517 review, commentary or revision – including pre- or post-publication stages.
- 518 Here’s an example of what the author contribution statement will look like in the
- 519 published paper:

520

521 BAC: Conceptualization; Data curation; Formal analysis; Funding acquisition;

522 Investigation; Methodology; Project administration; Resources; Supervision;

523 Validation; Visualization; Writing—original draft; Writing—review & editing. LS:

524 Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation;

525 Methodology; Supervision; Validation; Writing—review & editing. NT: Data curation;

526 Formal analysis; Investigation; Validation; Writing— review & editing.

527 Click [here](#) for more information on the CRediT contributor roles taxonomy.

528

529 Article types and lengths

- 530 • Research article: No limit (under 7500 words recommended)
- 531 • Review: No limit
- 532 • Forum: No limit
- 533 • Short Communication: 2,000 words or less (not including abstract, references, or
- 534 figure and table legends)
- 535 • Letter to the Editor: 2,000 words or less

536 For explanations of the different article types, please see the Article Types section of

537 these author instructions.

538

539 Language

- 540 • English. A second abstract in a second language is permitted. Authors are responsible
 - 541 for the accuracy of non-English abstracts.
 - 542 • Manuscripts with poor English will be withdrawn before review. Those authors are
 - 543 encouraged to pursue English assistance prior to resubmission. For a professional
 - 544 editing service, ESA journals have a partnership with the [Charlesworth Group](#),
 - 545 whereby ESA members receive a 10% discount on editing services. The discount is
 - 546 automatically applied if authors follow the hyperlink above.
- 547

548 Acceptable file types

549

- 550 • Main document: doc, docx, rtf

- 551 • Tables: Editable tables at the end of the main document. xls and xlsx files are not
552 accepted (except as supplementary files)
553 • Figures: tif (preferred), eps (preferred), rtf, doc/docx, ppt/pptx, pdf, ps, psd, ai, png,
554 gif* (please see “Videos and Animations” section).
555 • Videos: mp4
556 • Supplementary files: Most file types accessible to users. Extremely large files should
557 be uploaded in a third-party repository.
558

559 **Plagiarism and text recycling**

560 All submitted papers are evaluated for excessive direct copying through CrossRef’s
561 Ithenticate service. Papers should be written in the authors’ own words. Direct copying
562 of sentences or paragraphs, even if the original source is cited or if it is your own
563 previous work, is unacceptable (although some overlap is expected in materials and
564 methods). For more information, please see the Publication Ethics section of these
565 author instructions.
566

567 **Theses, dissertations, and pre-prints**

568 If your paper (or a previous version of it) was posted on a pre-print server or is part of a
569 thesis or dissertation that has been published online or in an institutional repository,
570 please note this in your cover letter so that it won’t be flagged for plagiarism.
571

572 **CrossRef Funding Data Registry**

573 In order to meet your funding requirements authors are required to name their funding
574 sources, or state if there are none, during the submission process. For further
575 information on this process or to find out more about CHORUS, [visit the CHORUS](#)
576 [initiative](#).
577

578 **Previous rejections**

579 Papers that have been rejected from one ESA journal cannot be resubmitted to any other
580 ESA journal. Papers that have been withdrawn can be resubmitted to the same journal or
581 another ESA journal. Authors whose papers have been rejected are entitled to appeal
582 their rejection to the journal’s editorial board. More information on the appeals process
583 can be found on the [Journal Policies](#) page.

584 **Statistics and sample size**

585 Statistics should be fully reported (i.e., F-value, both degrees of freedom [treatments
586 and replicates], and exact P-value [unless it's less than 0.001]). Furthermore, the paper
587 will be withdrawn if Duncan’s Multiple Range Test is used for papers that do not deal
588 with plant resistance. For more information on statistics, please see the Statistics section
589 of these author instructions.

590 Papers that have insufficient sample sizes (e.g., only a single year of data collected at
591 one location for either insect surveys, pesticide studies, or other field data) are
592 immediately withdrawn. The duration and size of trials/sampling must be biologically
593 significant.

594 **Plant extracts and essential oils**

595 For papers that test the efficacy of plant extracts or other compounds on control or
596 behavior modification of insects, the concentrations of the chemical constituents must
597 be listed. Reports on the use of essential oils (EO) and botanically derived compounds
598 as attractants, repellants, and insecticides must meet the following criteria for
599 publication in the *Journal of Medical Entomology*.

- 600 1. Manuscripts on essential oils/botanicals should include more information than
601 contact toxicity or repellency. There should be an element of either physiology,
602 cross-resistance, environmental persistence/fate, or non-target effects.
- 603 2. All studies should include a positive control so data on multiple compounds can be
604 directly compared. For repellants, the preferred positive control is DEET (Maia &
605 Moore 2011).
- 606 3. Experiments involving dose responses and estimation of LC50 or EC50s should
607 follow general guidelines given by (Burgess et al. 2021). The dose range should
608 include responses between 20 and 80%. Statistics should be reported in accordance
609 with Journal policies.
- 610 4. Manuscripts should not claim botanical or natural compounds are inherently safer
611 or more efficacious than synthetic compounds without supporting evidence (Trumble
612 2002).
- 613 5. Small sample sizes (<20) should not be converted to percentage data for analyses
614 (Jaeger 2008).
- 615 6. Chemical analyses of component compounds must be included in the study.

616
617 Burgess ER, King BH, Geden CJ. 2020. Oral and topical insecticide response bioassays
618 and associated statistical analyses used commonly in veterinary and medical
619 entomology. *J. Insect Sci.* 20(6):1-9. <https://doi.org/10.1093/jisesa/ieaa041>

620 Jaeger TF. 2008. Categorical data analysis: Away from ANOVAs (transformation or
621 not) and towards logit mixed models. *J. Mem. Lang.* 59(4):434–446.
622 <https://doi.org/10.1016/j.jml.2007.11.007>

623 Maia MF, Moore SJ. 2011. Plant-based insect repellents: a review of their efficacy,
624 development and testing. *Malar. J.* 10(Suppl 1):S1-S11. 10.1186/1475-2875-10-S1-S11

625 Trumble JT. 2002. Caveat emptor: Safety considerations for natural products used in
626 arthropod control. *Amer. Entomol.* 48(1):7-13. <https://doi.org/10.1093/ae/48.1.7>

627

628 Petri dish tests

629 Petri dish experiments are not accepted unless they contain a field, semi-field, or
630 greenhouse test.

631

632 **Personal communications**

633 Personal communication citations should be accompanied by a letter from the person
634 being cited giving permission to use him or her as a citation and verifying the claim
635 being cited. This letter should be uploaded as a supplementary file.

636

637 **Abbreviations**

638 Abbreviations should be used sparingly. Standard abbreviations for measurements
639 according to Scientific Style and Format, 8th edition, are acceptable, as well as common
640 abbreviations that improve the readability of a manuscript (e.g., DNA, PCR). All other
641 abbreviations used should be defined at the first use.

642

643 **Publication Ethics**

644 JME is committed to ethical behavior in all aspects of scholarly publishing. Please
645 ensure your paper meets the following ethical criteria:

- 646 • The author list is complete and correct. Please see the “[Journal Policies](#)” page for
647 authorship information and policies.
- 648 • No portions of text are directly copied from other sources, including one’s own
649 previous papers (although some overlap is tolerated in materials and methods).
650 Direct quotes should be placed in quotation marks. All manuscripts undergo a
651 plagiarism test before they are sent out for review.
- 652 • The data have not been published elsewhere. Data published in another paper,
653 including in a paper in another language, may not be published again. If portions of
654 data published previously are being used, the author must provide explicit written
655 consent from the publisher of the previous paper to reuse the data.

656
657 **Experimental Ethics**

658 Research published in JME must adhere to minimal ethical and compliance
659 requirements for medical, veterinary, and wildlife conservation research. Medical
660 entomology research may include human subjects and/or domestic and wild animals and
661 therefore requires that authors reference compliance protocols to indicate adherence to
662 federal, state, and local regulations, permits, and authorizations. International authors
663 should reference similar compliance documents from their government and/or
664 institution.

665 Listed below is a minimal series of basic requirements requested from USA and
666 international researchers to be included, as needed, within an ethical section positioned
667 in the Materials and Methods section of each manuscript:

- 668 1. Biological Use Authorization (BUA). Surveillance, epidemiological, and
669 experimental infection studies with pathogens require containment for diagnostics
670 and culture depending upon the virulence of the organism and the risk of
671 vectorborne, contact, and/or aerosol transmission. Descriptions of appropriate
672 containment for different biosafety levels can be [downloaded as a pdf](#).
673 A search engine and database to determine the Risk Group of the organism[s]
674 concerned can be found at the [ABSA International website](#).
675 Researchers should report their institution’s required compliance review and
676 approved containment level BUA protocol for the pathogen(s) or arthropods used.
- 677 2. Institutional Review Board (IRB) compliance. Use of human subjects in research
678 must be approved by IRB committees adhering to [US Department of Health and](#)
679 [Human Services guidelines](#). Each organization may have different interpretations of
680 guidelines required for human subject activities which may range from surveys,
681 house entry for arthropod collection, use of humans to feed arthropods, use of
682 humans as bait for sampling host-seeking insects, test subjects for candidate
683 repellents, etc.¹
- 684 3. Institutional Animal Care and Use Committee (IACUC) compliance. Use of animals
685 in research must adhere to protocols meeting minimal ethical requirements for
686 collection, maintenance, and experimental procedures. Research done within the
687 USA or funded by USA agencies must adhere to [requirements described](#) by the US
688 National Institutes of Health, and these protocols should be appropriately referenced.
- 689 4. Sampling wildlife. Most countries and states/provinces/districts require permits to
690 collect vertebrate animals and some insects for research purposes. This is especially
691 true for migratory species, such as birds, where international agreements are in place;

692 for example, see [permitting requirements](#) for collecting and banding birds in North
693 America.
694 An example of state permits required for taking or trapping and release of wildlife
695 within California can be found at [Department of Fish and Wildlife website](#).
696 Additional permits may be required for sampling on wildlife refuges or nature
697 conservatory properties. Reference to these permits should be required to ensure
698 sampling was done in compliance with regional oversight, especially for endangered
699 or threatened species.

700 5. Transport and release of organisms. With the increasing use of genetically modified
701 arthropods for population or pathogen control, medical entomologists must adhere to
702 correct oversight governing production and release. The US Department of
703 Agriculture has [strict requirements](#) for the transport and/or release of organisms as
704 well as experimental use permitting for applications of experimental compounds for
705 arthropod control.

706 The Biotechnology Quality Management System (BQMS) Program within the
707 USDA helps organizations, including small businesses and academic researchers,
708 analyze the critical control points within their management systems to better
709 maintain compliance with the APHIS regulations (7 CFR part 340) for the import,
710 interstate movement, and field release of regulated genetically engineered (GE)
711 organisms.

712 ¹Aultman KS, Walker ED, Gifford F, et al. 2000. Managing risks of arthropod vector
713 research. *Science* 288 (5475): 2321-2322. DOI: 10.1126/science.288.5475.2321

714

715 **Conflicts of interest**

716 Potential conflicts of interest include any relationships of a financial or personal nature
717 between an author or coauthor and individuals or organizations which, in theory, could
718 affect or bias an author's scientific judgment, or limit an author's freedom to publish,
719 analyze, discuss, or interpret relevant data.

720 Sources of financial support originating outside the coauthors' home institution(s) for
721 any aspect of a study must be indicated in the Acknowledgments section of the paper.
722 Financial support includes not only funding, but gratis provision of materials, services,
723 or equipment. Any additional potential conflicts of interest, not covered in the
724 acknowledgments of financial support, must be revealed to the editor at submission, and
725 disclosed in a statement immediately following the Acknowledgments.

726 If an author or coauthor has entered into an agreement with any entity outside that
727 authors' home institution, including the home institution of another coauthor, giving
728 that entity veto power over publication of the study or over presentation, analysis,
729 discussion, or interpretation of any results of the study, whether or not such veto power
730 was exercised, this information must be disclosed in a statement immediately following
731 the Acknowledgments.

732

733 **Article Types**

734 **Research**

735 Research articles report original observations and experiments, the results of the
736 experiment, and a discussion of the significance of the results. There is no word limit
737 for research articles.

738

739 **Review**

740 Review articles review and synthesize current information on a topic. Review articles
741 can also contain historical threads of important ideas (i.e., are not confined to recent
742 citations). There is no word limit for review articles.

743

744 **Forum**

745 Forum articles are authored by acknowledged leaders in the field, review a research
746 area, and include a stimulating, thought-provoking discussion that focuses on important,
747 and sometimes controversial, issues. They should provide an innovative approach to
748 current thought and speculate about future research directions.

749

750

751 **Short Communications**

752 Short communications should be similar to a research article, but with briefer Materials
753 and Methods and Discussion. Total length should be 2,000 words or less.

754

755 **Letter to the Editor**

756 JME will consider submissions in the form of a letter to the editor in which the authors
757 express their viewpoint on scientific issues. Appropriate content can include comments
758 or criticisms in reference to a published paper, whether or not in an ESA journal, or
759 comments and opinions unrelated to a specific published paper. A letter will be limited
760 to 2,000 words, 10 references, and one table or figure.

761 The Editor-in-Chief (EIC) will judge whether a submitted letter merits consideration for
762 potential publication based on relevance, inherent interest, and coherence of the
763 submission, but with a view to allowing a range of opinions to be expressed. If the EIC
764 considers the submission to be suitable in principle, he/she will send it to at least one
765 anonymous reviewer for comments and will edit it for style and appropriate language
766 before returning it to the corresponding author for revisions. More information on letters
767 to the editor can be found on our Journal Policies page.

768

769 **Title Page**

770 The title page should include:

- 771 1. *Corresponding author*: Include full name, mailing address, telephone number,
772 and email address.
- 773 2. *Title*: Should be as short as possible. Only include common names that are listed
774 in the ESA Common Names of Insects & Related Organisms. Do not include authors
775 of scientific names. Insert “([Order]: [Family])” immediately after the name of the
776 organism.
- 777 3. *Author list*: Include all authors in the order the names should be published.
- 778 4. *Affiliation line*: Include full addresses of all authors. If there are multiple
779 affiliations, designate through numbered footnotes.
- 780 5. *Abstract*
 - 781 a. 250 words or less.
 - 782 b. Give scientific name and authority at first mention of each organism.
 - 783 c. Do not cite references, figures, tables, probability levels, or results.
 - 784 d. Refer to results only in the general sense.
 - 785 e. A second abstract in a second language is permitted.
- 786 6. *Keywords*

- 787 a. Below the abstract, provide three to five keywords, separated by commas.
788 b. Do not use abbreviations, combined keywords, or species names.

789
790

791 **Body**

792 **Introduction**

793 Clearly state the basis of your study along with background information and a statement
794 of purpose.

795

796 **Materials and Methods**

797 Include a clear and concise description of the study design, experiment, materials, and
798 method of statistical analysis.

799

800 **Results**

801 Clearly present the results. Do not include interpretation of results or interpretation of
802 statistical analysis—simply present the results of the experiment and the results of the
803 statistical analysis. Data listed in tables should not be listed in the results; instead, refer
804 to the table.

805

806 **Discussion**

807 Interpret and discuss results of the study and their implications. Include suggestions for
808 direction of future studies, if appropriate.

809

810 **Acknowledgments**

811 Place the acknowledgments after the text. Organize acknowledgments in paragraph
812 form in the following order: persons, groups, granting institutions, grant numbers, and
813 serial publication number.

814 Following the Acknowledgments, you may {{include a statement of author contribution
815 outlining the specific contributions of each author to the article. A statement of author
816 contribution is welcomed but not required.

817

818 **References and in-text citations**

819 The ESA Journals style is based on the Council of Science Editors 8th Edition Name-
820 year style.

821 In-text citations:

822 For materials with one author, enclose the first author's surname and the publication
823 year in parentheses, for example (Chang 1999) or (Smith 1970, 1975) to cite multiple
824 works from the same author. For materials with two authors use both authors' surnames
825 and the year of publication: (Mazan and Hoffman 2001). For 3 or more authors use the
826 first author's surname and "et al." like this example: (Ito et al. 1999). Finally, to cite
827 more than one reference: list materials chronologically as follows: (Singh 2011,
828 Davidson 2015, Harding 2018).

829 Here are some basic formatting points for the bibliography:

- 830 • Only reference published and formally accepted (in press) articles.

- 831 • List references alphabetically by first author surname. List multiple references from
832 the same author chronologically.
- 833 • Add an alphabetic designator to the year in the in-text and end reference when there
834 are references from the same author in the same year, for example: (Johnson 2023a,
835 2023b)
- 836 • Author names are given surname first, followed by initials—with no punctuation
837 except for commas between authors and a period at the end.
- 838 • Include all author names unless there are more than 3. If a reference has 4 or more
839 authors, give only the first 3 names followed by “et al.” and the publication year.
- 840 • Abbreviate journal titles according to the List of Title Word Abbreviations: [Access to](#)
841 [the LTWA | ISSN](#) (see examples)
- 842 • Journal of Medical Entomology: J. Med. Entomol.
- 843 • Journal of Economic Entomology: J. Econ. Entomol.
- 844 • Annals of the Entomological Society of America: Ann. Entomol. Soc. Am.
- 845 Do not abbreviate non-English titled journals.
- 846 Systematics-related articles may specify that all serial titles be spelled out for final
847 publication.
- 848 When available, include the stable doi URL at the end of the reference or the doi.
- 849

850 **Sample reference styles**

851 *Journal Article*

852 Author surname(s) and initial(s), et al. Publication year. Article title. Abbreviated
853 Journal Title. Volume number (issue number):start page-end page. [stable doi URL] or
854 DOI:doi
855 Schmidt LS, Schmidt JO, Rao H, et al. 1995. Feeding preference and survival of young
856 worker honey bees (hymenoptera: Apidae) fed rape, sesame, and sunflower pollen. J.
857 Econ. Entomol. 88(6):1591-1595. <https://doi.org/10.1093/jee/88.6.1591>.

859 *Book*

860 Author surname(s) and initial(s), et al. Publication year. Editor(s). *Book title*, edition.
861 Place Published: Publisher. Pages.
862 Gravena S, Sterling W, Dean A. 1985. *Abstracts, references, and key words of*
863 *publications relating to the cotton worm Alabama argillacea (Huebner), (Lepidoptera:*
864 *Noctuidae)*. College Park, MD: Entomological Society of America. 136 p.

866 *Section/Chapter in Book*

867 Author surname(s) and initial(s), et al. Publication year. Title of Chapter in an Edited
868 Book. In: *Editor(s)*. *Book Title*. Edition. Place Published: Publisher. Pages.
869 Corporations or Organizations as authors
870 Organization. Publication year. Title. Abbreviated journal title. Available from: URL
871 White House. 2015a. National strategy to promote the health of honey bees and other
872 pollinators. Pollinator Health Task Force. Available from
873 [https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/Pollinator%20](https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/Pollinator%20Health%20Strategy%202015.pdf)
874 [Health%20Strategy%202015.pdf](https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/Pollinator%20Health%20Strategy%202015.pdf)
875 White House. 2015b. Pollinator research action plan. Report of the Pollinator Health
876 Task Force. Available from
877 [https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/Pollinator%20](https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/Pollinator%20Research%20Action%20Plan%202015.pdf)
878 [Research%20Action%20Plan%202015.pdf](https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/Pollinator%20Research%20Action%20Plan%202015.pdf)

879

880 *Patents*

881 Inventor(s), Assignee, Assignee name. Year. Title. Country Patent Number.

882 Pound M, Miller A, LeMeilleur A. 1994. Device and method for use as an aid in control
883 of ticks and other ectoparasites on wildlife. U.S. Patent #5,367,983.

884

885 *Conference Paper*

886 Author surname(s) and initial(s), et al. Publication year. Title. Paper Presented at:

887 Conference Name. Publisher; Conference Location.

888

889 *Conference Proceedings*

890 Editor(s). Publication year. Title. Conference name; Date year of Conference;

891 Conference Location. Place Published: Publisher.

892

893 *Theses/Dissertations*

894 Author surname(s) and initial(s), et al. Publication year. Title [Thesis type]. Place

895 Published: University. URL if available.

896 Barrufaldi APF. 2015. Temperatures of constant and floating influence on the biological

897 characteristics of *Euschistus heros* (Fabricius) (Hemiptera: Pentatomidae) in successive

898 generations [Master's dissertation]. Botucatu (Brazil): Universidade Estadual Paulista

899 Júlio de Mesquita Filho. <http://hdl.handle.net/11449/135938>.

900

901 **Data and Software Citation**

902 JME supports the [Force 11 Data Citation Principles](#) and requires that all publicly
903 available datasets be fully referenced in the reference list with an accession number or
904 unique identifier such as a digital object identifier (DOI). Data citations should include
905 the minimum information recommended by [DataCite](#):

906 [dataset]* Author surname(s) and initial(s), et al. Publication year. Title.

907 (repository or archive name). Identifier

908 *The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly
909 identify and tag the citation. This tag will be removed from the citation published in the
910 reference list.

911

912 Software citations should include the minimum information recommended by

913 the [FORCE11 Software Citation Implementation Group](#):

914

915 Author/developer surname(s) and initial(s), et al. Release date. Title. Publisher.

916 (repository or archive name). Identifier

917 If there is an article describing the software, it is recommended to cite both the software
918 and the article.

919

920 **Tables**

921 • Tables should be editable tables in a Word document.

922 • If a table continues on more than one page, repeat column headings on subsequent
923 page(s).

924 • All columns must have headings.

925 • Leave no space between lowercase letters and their preceding values (e.g., 731.2ab).

- 926 • Do not footnote the title—use the unlettered first footnote to include general
927 information necessary to understand the title (e.g., define terms, abbreviations, and
928 statistical tests).
- 929 • Use approved abbreviations or abbreviations already defined in the text and define
930 others in the general footnote.
- 931 • Use the following abbreviations in the body or column headings of tables only: amt
932 (amount), avg (average), concn (concentration), diam (diameter), exp (experiment),
933 ht (height), max (maximum), min (minimum), no. (number), prepn (preparation),
934 temp (temperature), vs (versus), vol (volume), wt (weight) Jan (January), Feb
935 (February), Mar (March), April, May, June, July, Aug (August), Sept (September),
936 Oct (October), Nov (November), and Dec (December).

937
938
939

Figures

- 940 • Figures should be at least 300 dpi, or 1200 dpi for line graphs.
- 941 • The quality in which figures are submitted is the quality in which they will print—
942 please ensure figures are high quality.
- 943 • The following file types of figures are accepted: tif (preferred), eps (preferred), rtf,
944 ppt/pptx, pdf, ps, psd, ai, gif, png. Figures should be in their native format for best
945 quality.
- 946 • Figures should be prepared in CMYK colour.
- 947 • The quality in which figures are submitted is the quality in which they will print—
948 please ensure figures are high quality.
- 949 • Each figure should be submitted as an individual file. Please do not copy and paste
950 them into the main document.
- 951 • Maximum height: 240 mm.
- 952 • Maximum width (one-column figure): 82 mm.
- 953 • Maximum width (two-column figure): 171 mm.
- 954 • For more information on preparing figures, see OUP’s Author Resource Centre
955 on [figures](#).
- 956 • All authors are required to pay additional charges for colour figures. Authors may
957 elect to publish in grayscale in print and in colour online for no charge. Authors
958 electing to publish figures in colour online and in grayscale in the print edition must
959 include grayscale images with their submission files. Please make sure your images
960 are legible in grayscale and that image captions do not point to colored arrows,
961 markers, or descriptors.

962

Graphical Abstracts

964 Authors are encouraged to submit a graphical abstract as part of the article, in addition
965 to the text abstract. The graphical abstract should clearly summarize the focus and
966 findings of the article, and will be published as part of the article online and in PDF.
967 The graphical abstract should be submitted for peer review as a separate file, selecting
968 the appropriate file-type designation in the journal’s online submission system. The file
969 should be clearly named, e.g. *graphical_abstract.tif*. See [this page](#) for guidance on
970 appropriate file format and resolution for graphics. Please ensure graphical abstracts are
971 in landscape format.

972 [Design tips and more information about graphical abstracts](#).

973 Note that graphical abstracts will be subject to any print reproduction charges that the
974 journal levies for colour figures.

975
976

Supplementary Material

977 Supplementary Material may be submitted in the form of one or more files to
978 accompany the online version of an article. Such material often consists of large tables,
979 data sets, or videos that are not possible or convenient to present in print media.
980 Supplementary Material represents substantive information to be posted on the ESA
981 journal website that enhances and enriches the information presented in the main body
982 of a paper; however, the paper must stand on its own without the need for the reader to
983 access the supplementary information to understand and judge the merits of the paper.
984 All Supplementary Material must be provided at the time of manuscript submission and
985 will be distributed to reviewers as part of the normal peer-review process. It will not be
986 edited during production and will be published as submitted.

987 Supplementary Material should be:

- 988 • Referenced in the body of the main paper (e.g., Supp. Table S1), where a link will take
989 the online reader to the file.
- 990 • Be labeled with an appropriate title and caption.
- 991 • Citations for any literature referenced within a Supplementary Material file should be
992 listed in a References Cited section at the end of the file, even when a citation is
993 duplicated in the main body of the paper.
- 994 • Videos should be kept to a reasonable size to facilitate downloading by readers.

995
996

Videos and Animations

997 Videos should be submitted as .mp4 files, at the highest possible resolution, and include
998 a still image to represent the video in the PDF.
999 Please do not submit animated gif files, which may be published as single image.
1000 Instead, please convert the gif to an .mp4 file.
1001 If supplied alongside the manuscript and cited within the article text, published videos
1002 will appear as streamable content within the article body. We cannot use videos hosted
1003 on third-party sites such as YouTube, as the link may expire.

1004

Species Authority, Order, Family, and Common Names

- 1006 • Authors should provide the authority, order, and family for all organisms that are
1007 central to the paper (including plants, bacteria, and other non-arthropod organisms) at
1008 the first mention of the organism. It is the author's responsibility to provide accurate
1009 authority, order, and family information. Organisms mentioned in passing or whose
1010 importance to the paper is limited do not need to have full authority, order, and family
1011 listed, nor do mentions of common names of groups (e.g., mosquitoes, beetles, ticks,
1012 etc.).
- 1013 • If a species name is included in the title of a paper, either the ESA-approved common
1014 name or the Latin name, the order and family should also be provided. If the order and
1015 family of an organism is provided in the title of the paper, it does not need to be
1016 provided again in the abstract and main text.
- 1017 • If an organism is not listed in the title but is central to the paper, the order and family
1018 should be provided at first mention of the organism in both the abstract and the main
1019 text.
- 1020 • The taxonomic authority of an organism that is central to the paper should be given the
1021 first time the organism is mentioned in both the abstract and the main text, but not in

1022 the title. For tables that include lists of species, authority should be given for each
1023 species if it is the first time it is being mentioned in the paper.
1024 • If multiple organisms in the same genus are central to the paper, order and family only
1025 need to be provided for the first species mentioned in the genus. If multiple organisms
1026 are central to the paper, are in different genera, but are in the same order and family,
1027 order and family should be provided at first mention of each organism.
1028 • If two organisms that share the same order and family are mentioned in the title or
1029 listed in the text of the paper together, the order and family should be placed after the
1030 first species listed and does not need to be repeated after the second species.
1031 • A genus can be abbreviated after the first mention (except to start a sentence, in which
1032 case the genus should be spelled out). If two species belong to different genera but the
1033 genera start with the same letter, the first two letters can be used for abbreviations.
1034 • Only ESA approved common names should be used. Common names are lower case,
1035 except for proper nouns and their derivations.

1036
1037

Statistics

1038 All data reported (except for descriptive biology) must be subjected to statistical
1039 analysis. Results of statistical tests may be presented in the text, in tables, and in figures.
1040 Statistical methods should be described in Materials and Methods with appropriate
1041 references. Descriptions should include information such as sample sizes and number of
1042 replications. Only t-tests, Chi square, and analyses of variance require no citation. Cite
1043 the computer program user's manual in the References Cited.

1044
1045

Probit/logit

1046 When presenting results of probit/logit analysis, the following columns should be
1047 included in tables in the following order (left to right); n, slope + SE, LD (or LC) (95%
1048 CL), and chi-square. When a ratio of one LD versus another is given, it should be given
1049 with its 95% CI. Statistical tests to show what model best fits data intended to estimate
1050 the 99.9986% level of effectiveness should be presented to justify use of any model,
1051 including the probit model. Thus, we do not recommend use of the Probit 9 without
1052 tests to show that the probit model fits the data.

1053
1054

Analysis of Variance or t-test

1055 When presenting the results of analysis of variance or a t-test, specify F (or t) values,
1056 degrees of freedom, and P values. This information should be placed in parentheses in
1057 the text. Example: (F = 9.26; df = 4, 26; P < 0.001). If readability of the text is affected
1058 by the presence of repeated parenthetical statistical statements, place them in a table
1059 instead.

1060
1061

Regression

1062 In regressions, specify the model, define all variables, and provide estimates of
1063 variances for parameters and the residual mean-square error. Italicize variables in
1064 equations and text.

1065
1066

Variance and sample size

1067 Include an estimate of the variance (or standard error) and sample size for each mean
1068 regardless of the method chosen for unplanned multiple comparisons. The use of

1069 Duncan's Multiple Range Test (DMRT) is not acceptable as a mean separation test as it
1070 was designed to be a very liberal test intended to find even minor differences in
1071 resistance between plant lines used for breeding.

1072
1073 **Model Analysis, Guidelines, Equations, and Computer Code**

1074 **Model Analysis**

1075 At the beginning of the manuscript, authors should state clearly the goals of their model
1076 construction and analysis. Evaluation by reviewers depends upon these goals and the
1077 type of model. Authors should attempt to describe the main conclusions, limitations,
1078 and sensitivity of results to assumptions. For stochastic models, describe the variability
1079 in the results.

1080

1081 **Modeling Guidelines**

1082 The following guidelines pertain to any mathematical model calculated for purposes
1083 other than statistical analysis.

- 1084 • Authors must adequately describe both model structure and model analysis.
- 1085 • Authors must explain and justify original equations and computer programs or justify
1086 the selection of a published software package used in the computation of models.
- 1087 • Model structure and steps in the analysis must be described in the Materials and
1088 Methods section.
- 1089 • Without presenting extensive computer code, the text must permit an understanding of
1090 the model that would allow most mathematically inclined scientists to duplicate the
1091 work.
- 1092 • Present all equations that represent the biology of the system being modeled.
- 1093 • Unless their derivation is self-evident, show how the equations were derived and
1094 mention the underlying assumptions.
- 1095 • Express how the equations are solved over time and space.
- 1096 • Provide references for standard techniques (e.g., matrix manipulation, integration).
- 1097 • Define all variables and parameters in each equation and describe their units (e.g.,
1098 time, space, and mass).
- 1099 • In the Materials and Methods or Results section, present the range of parameter values
1100 included in the model, and describe the uncertainty in or range of validity of these
1101 values.

1102

1103 **Equations**

1104 Consult Mathematics into Type for correct formatting of equations and mathematical
1105 variables. Italicize all mathematical variables.

1106

1107 **Validation or Testing of Model Results**

1108 Data used for validation must be independent of data used to build or calibrate the
1109 model. Authors must state why the model did not require testing (e.g., theoretical
1110 study), why it cannot be tested (e.g., lack of data), or how it was tested.

1111

1112 **Structure of Computer Code**

1113 For models solved or simulated by computers, mention the programming language and
1114 computer used. Describe the important numerical methods used in calculating the model
1115 (e.g., integration and random number generation). Mention how the program's logic and

1116 algorithms were tested and verified. When published software is computed, provide a
1117 reference and state which procedures were used. Discuss in any section of the
1118 manuscript the limitations of the published software. Original computer programs
1119 should be made available at the request of reviewers and readers.

1120

1121 Taxonomic Papers

1122 **ICZN compliance**

1123 JIS is compliant with the International Code of Zoological Nomenclature, and the
1124 publishing processes of the journal ensure that new acts of nomenclature are considered
1125 valid under the code. JME is permanently archived with CLOCKSS, LOCKSS, and
1126 Portico in a manner that preserves the content and layout of the work.

1127

1128 **Nomenclatural Works and Zoobank Registration**

1129 You will be asked during the submission process whether your article contains a new
1130 nomenclatural act. If it does, in order to comply with ICZN regulations, the author will
1131 need to register the article in ZooBank and insert a nomenclatural statement, which
1132 includes a Life Science Identifier (LSID), into the article. The registration can be made
1133 at first revision of the article. Instructions for this process can be found [here](#). When
1134 published, your article will also include the online publication date, and the statement
1135 “Version of Record, first published online [online publication date], with fixed content
1136 and layout in compliance with Art. 8.1.3.2 ICZN.” Following publication, the editorial
1137 office will update your ZooBank entry with the DOI, Volume, and Issue information.
1138 When you have registered the paper, please send the article tracking number and LSID
1139 to the editorial office (pubs@entsoc.org) to record in the peer-review system.

1140

1141 **Taxonomic Style**

1142 Follow the *International Code of Zoological Nomenclature* for taxonomic style. Some
1143 specific areas to note:

- 1144 • Center the heading that indicates the name of the taxon in bold type.
- 1145 • Center figure numbers in parentheses under the main heading; do not use bold type.
- 1146 • Start all synonymies at the left margin with runovers indented.
- 1147 • Include authors and date.
- 1148 • References must appear in References Cited section.
- 1149 • Use telegraphic style throughout descriptions.

1150

1151 **Taxonomy Headings**

1152 Use only acceptable 3rd-level subheadings such as:

- 1153 • Male
- 1154 • Female
- 1155 • Material Examined
- 1156 • Type Material
- 1157 • Distribution
- 1158 • Etymology
- 1159 • Biology
- 1160 • Discussion

1161 Avoid using “Description” as a subheading.

1162

1163 **Dates**

- 1164 • Use Roman numerals I through XII to designate month of collection.
1165 • Use Arabic numerals 0000 through 9999 to designate collection years. Do not
1166 abbreviate other years, including the 21st century, except when explicitly transcribing
1167 exactly what appears on specimen labels.
1168 • Express dates in this format: day-month (use a Roman numeral)-year. Example: 2-V-
1169 97.

1170

1171 **Locality Other than Principal Types**

- 1172 • Start with the largest area followed by successively smaller areas separated by
1173 colons.
1174 • Capitalize countries.
1175 • Arrange data for each locality in the following order: count of specimens and sex or
1176 stage (as applicable), city or vicinity, date, collector, and depository. Example:
1177 MEXICO: Tamaulipas: 1 male, 1 female, Ciudad Mante, 15-III-97, K. Haack; 5
1178 females, Ciudad Victoria, 3-VII-99, C. Hughes, MCZ.
1179 • Arrange localities alphabetically.
1180 • Use a semicolon to separate data for different localities.
1181 • Define depositories in the Materials and Methods.

1182

1183 **Type Material**

1184 Start description with the principal type in capital letters. Follow this immediately with
1185 count and sex of specimens (use male and female symbols if possible), then place
1186 additional data in the order of locality, date, additional data, and collector. Separate
1187 these items with commas. Example: HOLOTYPE: 1 male, Locust Grove, VA, 22-X-98,
1188 on *Cercis canadensis*, R. H. Foote. PARATYPES: 2 males, same data.

1189

1190 **Voucher Specimens**

1191 Voucher specimens of arthropods serve as future reference for published names used in
1192 scientific publications. Authors are required to deposit voucher specimens in an
1193 established, permanent collection and to note in the published article that the expected
1194 deposition has been made, its location, and the collection accession number. Authors
1195 should contact the curator of a voucher repository before deposition concerning the
1196 procedures required for curation to ensure that the collection will accept the voucher
1197 materials. The designation and proper labeling of voucher specimens is the author's
1198 responsibility. When available, at least three specimens should be deposited. Each
1199 specimen should have the following information provided at the time of deposition:
1200 • Standard label data that are required for the specimens collection (i.e., locality, date of
1201 collection, collector, host, ecological data, whether the specimen is from a laboratory
1202 collection, etc.).
1203 • An identification label that includes the identifier and date of identification.
1204 • A label that designates the specimen as "voucher."

1205

1206 **Immutable Advance Access**

1207 *JME* publishes articles online ahead of inclusion in an issue via OUP's Advance
1208 Access.

1209

1210 In order to comply with the requirements of the International Commission on
1211 Zoological Nomenclature (ICZN) with regard to nomenclatural works, articles
1212 published by ESA's journals that include nomenclatural information will be immutable.
1213 Additionally, no changes will be allowed to any article without the publication of a
1214 correction clearly stating the changes that have been made. Therefore, it is the
1215 responsibility of the authors to carefully check their proofs for accuracy, and to notify
1216 the publisher of any changes that are necessary prior to Advance Access publication.
1217

1218 **Gene Sequencing**

- 1219 • Inclusion of a GenBank/EMBL accession number for primary nucleotide and amino
1220 acid sequence data is required.
- 1221 • Sequences from new species and new genes must indicate the proportion of the gene
1222 sequenced and should include data from both strands.
- 1223 • The accession number may be included in the original manuscript or the sequence
1224 may be provided for review and an accession number provided when the manuscript
1225 is revised.

1226

1227 **Availability of Data and Materials**

1228 Where ethically feasible, *JME* strongly encourages authors to make all data and
1229 software code on which the conclusions of the paper rely available to readers. We
1230 suggest that data be presented in the main manuscript or additional supporting files, or
1231 deposited in a public repository whenever possible. Information on general repositories
1232 for all data types, and a list of recommended repositories by subject area, is
1233 available [here](#).

1234 ESA journals are integrated with Dryad (www.datadryad.org), an online data repository.
1235 Upon submission, authors will be sent a link to easily deposit the full dataset(s) behind
1236 their research in Dryad. Datasets deposited in Dryad are given unique DOIs, linked to
1237 the corresponding paper, and are available to be reviewed by subject editors of the
1238 journal upon request. Depositing data in Dryad is optional.

1239 If you would like your paper to link to the dataset, data should be deposited prior to
1240 acceptance. Authors are required to pay Dryad for depositing data, but this fee is only
1241 charged if a paper is accepted.

1242

1243 **ORCID**

1244 *JME* requires submitting authors to provide an ORCID iD at submission to the journal.
1245 More information on [ORCID and the benefits of using an ORCID iD](#) is available. If you
1246 do not already have an ORCID iD, you can register for free via the [ORCID website](#).
1247 Coauthors are encouraged to link their ORCID iDs to their online review system
1248 accounts. Because the coauthor must login to the ORCID system to verify their identity,
1249 this process cannot be completed by the corresponding author or staff.

1250

1251 **Preprint Policy**

1252 Authors retain the right to make an Author's Original Version (preprint) available
1253 through various channels, and this does not prevent submission to the journal, however,
1254 preprint servers where papers are formally reviewed and a decision is issued will be
1255 considered previous publication and will not be accepted for review. Please note in the
1256 cover letter that the paper has been submitted to a pre-print server. For further
1257 information see our [Online Licensing, Copyright and Permissions policies](#). If accepted,

1258 the authors are required to update the status of any preprint, including your published
1259 paper's DOI, as described on our [Author Self-Archiving policy page](#).

1260

1261 **Immutable Advance Access**

1262 JME publishes articles online ahead of inclusion in an issue via OUP's Advance
1263 Access.

1264 In order to comply with the requirements of the International Commission on
1265 Zoological Nomenclature (ICZN) with regard to nomenclatural works, ALL articles
1266 published by ESA's journals, regardless of whether they include nomenclatural
1267 information, will be immutable; this means that no changes will be allowed to any
1268 article without the publication of an erratum clearly stating the changes that have been
1269 made. Therefore, it is the responsibility of the authors to carefully check their proofs for
1270 accuracy, and to notify the publisher of any changes that are necessary prior to Advance
1271 Access publication.

1272

1273 **Revised Papers**

1274 For revised papers, we have a few more formatting requirements than we do for new
1275 submissions, to ensure the paper is ready for publication if it is accepted.

1276 Response to reviews

1277 Provide a document listing how you changed your manuscript in response to each point
1278 mentioned by the reviewers. If you did not implement a change suggested by a
1279 reviewer, please explain why.

1280

1281 **Style**

1282 For any matters of editorial style not covered in these author guidelines, ESA journals
1283 adhere to the [Council of Science Editors \(CSE\) Style Guide](#).

1284

Measurements

1285 Use metric units. English units may follow within parentheses if needed.

1286

1287 **Nomenclature**

1288

- 1289 • Give full scientific name and authority at first mention of each organism (including
1290 plants and non-insect animals) in the abstract and again in the text.
- 1291 • Only use common names listed in the current [ESA Common Names of Insects &
1292 Related Organisms](#) online database. Common names should be lowercase, except for
1293 proper nouns and their derivations.
- 1294 • When possible, please provide as much genetic and/or colony information available is
1295 useful (for example, "Rockefeller colony of *Aedes aegypti* (L.)"). Including
1296 geographic origin and generations in culture is also useful, but may not always be
1297 known and is not required.

1298

1299 **Submissions of Cover Photographs**

1300 Authors are encouraged to submit insect photos for the cover of the journal. Photos
1301 must be of living (not pinned) insects and must be submitted as high-resolution (300 dpi
1302 or higher) image files. If you wish to crop your image to the exact dimensions of our
1303 cover, the dimensions to use are W: 222 mm x H: 203 mm; however, photos that do not

1304 match those dimensions can still be accepted. The insect species featured on the cover
1305 of a given issue must be mentioned in the issue in question.
1306 Photographers will be asked to give ESA one-time permission to use the photo on the
1307 journal cover and will retain their copyright of the photo.
1308 Submit photos to pubs@entsoc.org.

1309

1310 **Publication Fees**

1311 There are fees to publish in the Entomological Society of America journals, which may
1312 be offset by one of our publisher's many read and publish agreements or the
1313 membership status or geographic location of the authors. If you have any questions
1314 about the cost of publication, please email pubs@entsoc.org.